|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | |||||||
  Journal of the American Geriatrics SocietyVolume 53 Issue 6, Pages 983 - 990 Published Online: 1 Apr 2005 Journal compilation 2010 The American Geriatrics Society/Wiley Periodicals, Inc.
Abstract | References | Full Text: HTML, PDF (Size: 99K) | Related Articles | Citation Tracking  Caregiver-Specific Outcomes in Antidementia Clinical Drug Trials: A Systematic Review and Meta-Analysis Copyright © 2005 by the American Geriatrics Society KEYWORDS caregivers • cholinesterase inhibitors • metaanalysis ABSTRACTObjectives: To describe the range of caregiver-specific outcomes and approaches to their study within antidementia drug trials and to quantify the effect of cholinesterase inhibitors on burden and active time use of caregivers of persons with Alzheimer's disease (AD). Design: Systematic review of English-language publications and unpublished reports of antidementia clinical drug trials that included caregiver-specific outcomes. Study characteristics and methodological quality were summarized. Random effects meta-analyses were conducted for the outcomes of caregiver burden and active time use. Setting: Community. Participants: Informal caregivers of participants in clinical trials of antidementia drugs. Measurements: Burden, time use, psychological well-being, healthcare costs, and ease of use of or satisfaction with intervention. Results: Seventeen studies involving 4,744 subjects were identified. Four trials (n=1,594) met criteria for inclusion in the burden analysis, and six trials (n=2,286) met criteria for inclusion in the time-use analysis. Most investigations involved drugs now approved by the Food and Drug Administration for the treatment of AD; donepezil was the most frequently studied intervention in the set of studies. Methodological quality varied across trials. The weighted average effect sizes were Cohen's d=0.18 (95% confidence interval (CI)=0.04–0.32) and d=0.15 (95% CI=0.07–0.24) for the outcomes of caregiver burden and time use, respectively. Conclusion: Cholinesterase inhibitors have a small beneficial effect on burden and active time use among caregivers of persons with AD. Recommendations to enhance the quality and interpretability of AD clinical trials that involve caregiver-specific outcomes are presented. | 
|
